Oncopeptides Investor Relations Material
Latest events
Q2 2024
Oncopeptides
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Oncopeptides
Access all reports
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden
Key slides for Oncopeptides
Q2 2024
Oncopeptides
Q2 2024
Oncopeptides
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
ONCO
Country
🇸🇪 Sweden